Market Research Logo

Epilepsy Therapeutic Market in APAC 2017-2021

Epilepsy Therapeutic Market in APAC 2017-2021

About Epilepsy Therapeutic

Epilepsy is a neurological condition that affects the nervous system. It is characterized by the occurrence of two or more unprovoked seizures. A seizure is defined as the disruption of electrical communication between neurons. The central nervous system (CNS) disorders include several disorders and conditions such as epilepsy, Parkinson's disease, bipolar disorder, and depression.

Technavio’s analysts forecast the epilepsy therapeutic market in APAC to grow at a CAGR of 4.25% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the epilepsy therapeutic market in APAC for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off label drugs.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Epilepsy Therapeutic Market in APAC 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Eisai
  • GlaxoSmithKline
  • Pfizer
  • UCB
Other prominent vendors
  • Dainippon Sumitomo Pharma
  • Janssen Pharmaceutical (a division of Johnson & Johnson)
Market driver
  • High unmet medical need
  • For a full, detailed list, view our report
Market challenge
  • Technological advancements in non-invasive neuromodulation and seizure management devices - A threat to drug therapies
  • For a full, detailed list, view our report
Market trend
  • Reformulation of marketed drugs
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Epilepsy Therapeutic Market in APAC 2017-2021

Technavio recognizes the following companies as the key players in the epilepsy therapeutic market in APAC: Eisai, GlaxoSmithKline, Pfizer, and UCB.

Other Prominent Vendors in the market are: Dainippon Sumitomo Pharma and Janssen Pharmaceutical (a division of Johnson & Johnson).

Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is reformulation of marketed drugs. Drug delivery systems such as transdermal patches, extended-release (ER) formulations, and orally disintegrating tablets increase the efficacy of drugs either by increasing the patient compliance or by increasing the bioavailability of the drug. The reformulation of marketed drugs also provides an opportunity to grab patent term extensions, which can delay the entry of generic versions in the market.”

According to the report, one of the major drivers for this market is high unmet medical need. The epilepsy therapeutics market in APAC is currently witnessing a high unmet medical need in terms of the lack of any disease-modifying treatment. At present, drugs administered during epilepsy are intended to treat seizures, i.e., these are symptomatic in nature, which helps in suppressing symptoms (seizures) and provides substantial assistance to individuals.

Further, the report states that one of the major factors hindering the growth of this market is technological advancements in non-invasive neuromodulation and seizure management devices - A threat to drug therapies. A majority of the population treated with traditional AEDs still continue to suffer from their side effects such as weight gain, muscle spasm, blurred vision, dry mouth, and drowsiness. Hence, alternative methods were being investigated, and devices were developed for the individuals who do not respond to medications.



Companies Mentioned

Eisai, GlaxoSmithKline, Pfizer, UCB, Dainippon Sumitomo Pharma and Janssen Pharmaceutical (a division of Johnson & Johnson).

  • Executive summary
  • Scope of the report
  • Research Methodology
  • Introduction
    • Market outline
      • Table Global CNS therapeutics market segmentation based on disease type
      • Table Epilepsy therapeutics market scenario based on countries
  • Disease overview
    • Table Types of epilepsy disorder
    • Signs and symptoms
      • Table Signs and symptoms of epilepsy
    • Generalized seizure
      • Table Types of generalized seizure
    • Focal seizure
      • Table Types of focal seizure
    • Non-convulsive seizure
  • Market landscape
    • Market overview
      • Table Epilepsy therapeutics market in APAC snapshot
    • Market size and forecast
      • Table Epilepsy therapeutics market in APAC 2016-2021 (in $ million)
      • Table Opportunity analysis in epilepsy therapeutics market in APAC
    • Five forces analysis
      • Table Five forces analysis
  • Pipeline analysis
    • Table Pipeline landscape
    • Table Key clinical trials: Therapeutics
    • Table Key clinical trials: Enhanced drug delivery
    • Table Key clinical trials: Dietary supplement
  • Market segmentation based on product type
    • Table Segmentation of epilepsy therapeutics market in APAC on product type
    • Table Market share of epilepsy therapeutics market in APAC based on product type 2016
    • First-generation epilepsy therapeutics
      • Table Approval scenario: First-generation epilepsy therapeutics
      • Table First-generation epilepsy therapeutics market in APAC 2016-2021 ($ millions)
    • Second-generation epilepsy therapeutics
      • Table Second-generation epilepsy therapeutics market in APAC 2016-2021 ($ millions)
    • Third-generation epilepsy therapeutics
      • Table Third-generation epilepsy therapeutics market in APAC 2016-2021 ($ millions)
  • Geographical segmentation
    • Table Segmentation of epilepsy therapeutics market in APAC by geography 2016 and 2021 (%)
    • Table Epilepsy therapeutics market revenue in APAC by geography 2016-2021 ($ millions)
    • Table Epilepsy therapeutics market share in APAC by geography 2016-2021 (%)
    • Epilepsy therapeutics market scenario in Japan
      • Table Market scenario in Japan
      • Table Epilepsy therapeutics market in Japan 2016-2021 ($ millions)
    • Market scenario in Australia
      • Table Market scenario in Australia
      • Table Epilepsy therapeutics market in Australia 2016-2021 ($ millions)
    • Market scenario in China
      • Table Market scenario in China
      • Table Epilepsy therapeutics market in China 2016-2021 ($ millions)
    • Market scenario in India
      • Table Market scenario in India
      • Table Epilepsy therapeutics market in India 2016-2021 ($ millions)
  • Decision framework
  • Drivers and challenges
    • Market drivers
      • Table Epilepsy scenario in developed countries versus developing countries
    • Market challenges
      • Table Impact of loss of exclusivity for LYRICA in Canadian and European market ($ millions)
  • Market trends
    • Reformulation of marketed drugs
    • Emergence of new-generation AEDs
    • AEDs with novel mechanism of action
  • Vendor landscape
    • Competitive landscape
      • Table Competitive structure analysis of epilepsy therapeutics market in APAC 2016
  • Key vendor analysis
    • Eisai
      • Table Eisai: Key highlights
      • Table Eisai: Strength assessment
      • Table Eisai: Strategy assessment
      • Table Eisai: Opportunity assessment
    • GlaxoSmithKline
      • Table GlaxoSmithKline: Strength assessment
      • Table GlaxoSmithKline: Strategy assessment
      • Table GlaxoSmithKline: Opportunity assessment
    • Pfizer
      • Table Pfizer: Key highlights
      • Table Pfizer: Strength assessment
      • Table Pfizer: Strategy assessment
      • Table Pfizer: Opportunity assessment
    • UCB
      • Table UCB: Key highlights
      • Table UCB: Strength assessment
      • Table UCB: Strategy assessment
      • Table UCB: Opportunity assessment
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report